



Dr. Ayushi Purohit

Research Scientist

BRIEF PROFILE

My primary vision is to translate clinical research to bench side research. We are going to expand our efforts to harness the diversity of microbes that inhabit our bodies, known as the microbiome, in the development of innovative treatments for life-threatening diseases especially liver diseases. The intestinal microbiota and bacterial products can directly and indirectly affect the liver through various mechanisms, leading to a wide variety of liver diseases. This suggests a potential role for pre-, pro- and synbiotic products in the prevention or treatment of some liver diseases. Modulation of the gut microbiome by probiotics or fecal microbiota transplant ameliorates the progression of liver disease. Efforts will be made to prepare pills with single-microbe species or fecal microbiota transplantation that may improve the immune response and in-turn treat patients. Thus, clinical trials will be persuaded to explore gut bacteria to maintain homeostasis in form of probiotics or fecal microbiota transplant for metabolic disorders to expand the field of microbiome therapeutics.

Area of Interest: To modulate gut dysbiosis by focusing on:

- Artemis Dysbiosis kit would benefit from the identification and validation of specific ratio of bacterial taxa that are indicative of dysbiosis. Research efforts should focus on discovering reliable and robust biomarkers that can accurately discriminate between dysbiotic and healthy microbiota.
- Making oral fecal microbiota transplant (FMT) capsules will be “a good bridge” from FMT given via invasive methods which will emerge for better at analyzing individual patients’ microbiomes—and figuring out which microbial species are needed utmost. Oral FMT capsules are promising because of ease of administration and non-invasive delivery.

Collaborators

- Dr. Sanjay. Banerjee NIIPER Guwahati
- Dr. Bhabatosh Das, THSTI Faridabad

Contact Information

Email: ayushi.purohit@artemishospitals.com